Plain-English translation of NCT05168618 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination of two drugs — cabozantinib and — to see if they work together to control advanced prostate cancer in men whose cancer has progressed despite hormone therapy. Cabozantinib targets blood vessels and specific cancer-related pathways, while works by helping your immune system recognize and fight cancer cells. Researchers want to learn whether this medication combination can slow or stop the cancer's growth.
Men with advanced prostate cancer that no longer responds to standard hormone treatments have limited options and often face poor outcomes. This trial explores whether combining these two medications might offer a new, more effective treatment approach for this difficult-to-treat form of cancer.
You would take cabozantinib as a daily oral pill for 21 days, and receive as an intravenous infusion (through an IV) on day 1 of each 21-day cycle. This cycle repeats as long as the treatment is working and you are tolerating it well. You'll have regular visits for blood tests, imaging scans, and check-ups to monitor how your cancer is responding and how you're handling the medication. After treatment ends, you'll continue with follow-up appointments at 30 days and then every 3 months to track your progress.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States